This result is partially consistent with the results of a previous study conducted by Zhang et al., which found that PTPRT mutations may be considered as a potential indicators for assessing ICI efficacy in melanoma, NSCLC, and multiple other cancers (31). The gene discussed is PTPRT; the disease is cancer.